about
Repairing the broken market for antibiotic innovation.Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality.How Medicare could get better prices on prescription drugs.Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals.Towards new business models for R&D for novel antibiotics.International cooperation to improve access to and sustain effectiveness of antimicrobials.Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach.Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy.Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration-Approved Antibiotics, 2010-2015.Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets.Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980-2009.To the G20: incentivising antibacterial research and development.Accelerating global innovation to address antibacterial resistance: introducing CARB-X.Disproportionate Exposure to Antibiotics in Children at Risk for Invasive Pneumococcal Disease: Potential for Emerging Resistance and Opportunity for Antibiotic Stewardship.Patent buy-outs for global disease innovations for low- and middle-income countries.Tragedy and remedy: reparations for disparities in black health.Higher First Amendment hurdles for public health regulation.Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.What Will It Take to Address the Global Threat of Antibiotic Resistance?Market watch: Innovation in the preclinical antibiotic pipeline.INTRODUCTION: What Will It Take to Address the Global Threat of Antibiotic Resistance?Will longer antimicrobial patents improve global public health?Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations.Antimicrobial Resistance: The Authors Reply.The Drug Quality and Security Act--mind the gaps.Introduction and geographic availability of new antibiotics approved between 1999 and 2014Disease management: legal strategies for the next generation of managed careMarket-based licensing for HPV vaccines in developing countriesShould access to medicines and TRIPS flexibilities be limited to specific diseases?Smoking and the First AmendmentImproving antibiotic markets for long-term sustainabilityIntroduction: pharmaceutical innovation: law & the public's healthForeword--Will HPV vaccines prevent cervical cancers among poor women of color?: global health policy at the intersection of human rights and intellectual property lawQuestions about the 10 x '20 InitiativePunishing health care fraud--is the GSK settlement sufficient?Clinical trial transparency--antidote to weaker off-label-promotion rules?The Fight Against Multidrug-Resistant BacteriaEvaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercializationA shot in the arm for new antibioticsA Perspective on Incentives for Novel Inpatient Antibiotics: No One-Size-Fits-All
P50
Q35554004-C336206D-382D-4BAE-B7B8-21D4356338D5Q36051713-2782985C-CEE8-4F0D-9AB2-D8DC54BC8460Q37567122-DD0566AF-6DCE-414E-A157-8A9239CAE228Q37785721-54B5CCA3-D043-430C-BECB-FB8EBDABFC6BQ37858065-7C4ABD61-F5F3-4AF8-AE4D-5942E3B40BF4Q38646936-C9B0925D-F484-49F4-A057-C71A0BB11B6FQ38795740-E2DF52C1-A1E9-4D38-84CC-88D3B14DB44FQ38824288-7D3647B8-AF6F-45F9-BFFE-63239F20B3F0Q38848080-59AEEE9F-0BB5-49E7-8D44-36AD5A134E31Q39331121-564A8818-B53E-486B-B029-FC68A654574FQ39340620-4E2DF426-5A11-43FD-BCD9-90C71488B203Q40142920-AB522AF0-101E-4D66-8023-692A58A3ABE0Q40596351-A17F5D28-E30A-42B4-88CC-7BA0563047CEQ41989559-78734B7F-CC54-4D34-B788-6DC7F32D9181Q44184369-6E23EBAC-D366-418C-BA84-6E81013DC077Q44924245-48AD772C-99AE-4950-BE58-722BB7783096Q46945498-5E602AB1-B996-4EBD-9AAA-C5CACE1921ABQ47765000-C1F38BF3-1A44-499F-A9F2-C4F4D0BE2930Q48034741-5025CF6A-8FEE-458D-A75D-DDD7433C92CCQ49570927-13DEB5D0-2774-4A5A-99E4-CC385B881FFDQ50948961-40359D93-0724-4081-BFF0-25824D307D5BQ51103968-C8FF8895-0D12-4AF4-AE61-FD8E7BA8C137Q52597584-DE3D9430-8E05-47CE-BEFD-4C247076AD89Q53767484-0B743F40-B011-47F3-BB09-54A9D3A445F4Q54398545-4DB4F1FA-A84D-41FC-A389-DB1BCBCDE971Q57459900-E76394A0-BF64-48C3-9749-B53AF5EDE4AEQ73323838-22E47E8D-DD4B-4790-9B8D-F64843E852AAQ80460448-B1140A97-0ACE-4315-874B-774A43CBE15DQ81773368-FB04638A-44FB-4420-B6CC-B12B675C5C67Q82849249-5E81D9B2-A912-4363-B9FE-E03A0894951FQ83551627-85435DC0-7AB2-45A2-9E95-84CB34237B2DQ83986794-3D9A2BDD-8340-4BEE-A419-D95437B1479AQ84444917-70125BB1-87DA-4AF9-A39D-38942574F7EBQ84788599-2707BABD-FEC4-4E6D-A8A3-2D250969C2B9Q84964695-2263FA62-E14A-4BAE-8394-A2B102D7D47FQ88204788-21EF1CA5-AEC7-4654-B5B8-C8249796F64EQ89383030-69068B48-0CEA-40AC-8602-B736B32215C8Q90277383-F30524AA-995F-45FB-9A2E-161C1D64EF12Q90442042-0BF8443E-8896-4178-9DC3-EC72DBD83EDFQ91149072-8C22C785-91E0-48A6-A2B8-C85BDD4CB940
P50
description
researcher
@en
wetenschapper
@nl
name
Kevin Outterson
@en
Outterson K
@nl
type
label
Kevin Outterson
@en
Outterson K
@nl
altLabel
Outterson K
@en
prefLabel
Kevin Outterson
@en
Outterson K
@nl
P106
P31
P496
0000-0003-2513-3216